Search results
Results from the WOW.Com Content Network
ImmunoGen (IMGN) reports encouraging third-quarter results. Top-line data readout from pivotal studies on its lead candidate, mirvetuximab soravtansine, remains on track.
In this article we will check out the progression of hedge fund sentiment towards ImmunoGen, Inc. (NASDAQ:IMGN) and determine whether it is a good investment right now. We at Insider Monkey like ...
And this weekend, rumors continue to build that Trump's team may be arranging a buyout of Intel (Nasdaq: INTC) that could be funded by Elon Musk. Leaks of the rumor sent Intel up 9.25% in trading ...
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Need help? Call us! 800-290-4726 Login / Join. Mail
For premium support please call: 800-290-4726 more ways to reach us